Fetal growth restriction.
| Publicado en: | Lancet Vol. 355; no. 9212; pp. 1367 - 1369 |
|---|---|
| Autores principales: | , , |
| Formato: | commentary letter Journal Article |
| Publicado: |
Lancet
4/15/2000
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=126422524&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 126422524 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 01406736 LAN jtl: Lancet issn: 01406736 maglogo: N pubinfo: dt: 4/15/2000 vid: 355 iid: 9212 pid: 1297 pub: Lancet place: Philadelphia, Pennsylvania artinfo: ui: 126422524 126422524 NLM10776773 126422524 10.1016/s0140-6736(05)72601-5 NLM10776773 126422524 ppf: 1367 ppct: 2 formats: fmt: @attributes: type: P tig: atl: Fetal growth restriction. aug: au: Carbonne, B Jannet, D Milliez, J sug: subj: Pre-Eclampsia Drug Therapy Fetal Growth Retardation Chemically Induced Antihypertensive Agents Adverse Effects Clinical Trials Atenolol Adverse Effects Blood Pressure Drug Effects Atenolol Therapeutic Use Human Infant, Newborn Bias (Research) Gestational Age Pregnancy Female Risk Factors Antihypertensive Agents Therapeutic Use Validation Studies Comparative Studies Evaluation Research Multicenter Studies Infant, Newborn: birth-1 month Female pubtype: Academic Journal doctype: commentary letter Journal Article ougenre: Unknown ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|